The FDA has cleared Jubilant Therapeutics' IND application for JBI-778, an oral, brain-penetrant and selective protein arginine methyl transferase 5 (PRMT5) inhibitor, for the treatment of solid tumors with brain metastases and primary brain tumors, including high-grade glioma.
It has been previously demonstrated that MYCN amplification frequently occurs in high-risk neuroblastoma (NB), and it is correlated with an undifferentiated phenotype and poor prognosis.
Helios-Huaming BioPharma has synthesized new substituted salicylamide compounds acting as protein-arginine deiminase type-4 (PADI4) inhibitors reported to be useful for the treatment of cancer, rheumatoid arthritis and ischemia-reperfusion injury, among other disorders.
Shanghai Hengrui Pharmaceutical and Jiangsu Hengrui Medicine have described cyclohexadiimide derivatives reported to be useful for the treatment of cancer and neurological disorders.
Researchers at Beijing Institute of Pharmacology and Toxicology have reported the discovery of novel CRBN-recruiting epidermal growth factor receptor (EGFR) degraders as candidates for the treatment of non-small cell lung cancer (NSCLC). Synthesis and optimization of a series of CRBN-recruiting EGFR degraders led to the identification of compounds [I] and [II] as the lead candidates.
The University of Texas System has described new nimbolide derivatives reported to be useful for the treatment of cancer, especially poly [ADP-ribose] polymerase (PARP)-resistant cancer.
Jinan University and Guangzhou Lixin Pharmaceuticals have presented new 2-aminopyrimidine compounds acting as tyrosine-protein kinase JAK3 inhibitors reported to be useful for the treatment of cancer and inflammation.
RSS